Side effects of the DSIP peptide: safety, risks, interactions and FDA status

Delta sleep-inducing peptide (DSIP), also known as emideltide, has been linked to several adverse effects in limited human studies. Reported symptoms included headache, nausea, dizziness, sweating, temporary agitation and low blood pressure. However, the overall safety profile of DSIP remains unclear. Most human studies were small, short-term and conducted decades ago. They primarily used DSIP administered intravenously under medical or research supervision. This differs significantly from subcutaneous injections and nasal sprays, which are now frequently discussed or sold online.

Therefore, the main safety issue is not a long list of confirmed side effects of DSIP. A greater limitation is the lack of sufficient data to determine how often adverse events occur, how severe they might be, whether they are dose-dependent, and what the consequences of repeated or long-term exposure might be.

Some historical studies on insomnia indicated few or no significant adverse events. However, they involved very small participant groups and short treatment periods. In a larger, uncontrolled study involving individuals undergoing alcohol or opioid withdrawal, several mild reactions and cases of low blood pressure were reported. Some of these symptoms may also have been due to the withdrawal syndrome itself [1–4].

Product quality represents an additional source of uncertainty. Findings regarding carefully prepared DSIP administered intravenously in studies from several decades ago cannot confirm the safety of a contemporary product sold online as „research grade”, a subcutaneous preparation or a DSIP nasal spray.

In a 2026 assessment, the US Food and Drug Administration (FDA) concluded that substances related to emideltide have not been sufficiently characterised for human use. The FDA highlighted peptide impurities, aggregation, endotoxin testing, and the potential for immunological reactions. The agency also proposed that emideltide in free base and emideltide acetate forms should not be included on the Section 503A bulk drug substances list [1,5].

What side effects of DSIP have been reported?

Most of the published information regarding the side effects of DSIP comes from historical studies utilising intravenous administration. Considerably less is known about the intranasal and subcutaneous routes, which are now frequently discussed.

The 2026 FDA review identified human studies in which a total of 209 participants were administered intravenous emideltide in amounts ranging from 25 to 150 nmol/kg. Treatment periods ranged from one to 15 days. Crucially, the FDA found no clinical safety data regarding the proposed subcutaneous route [1].

One of the important sources of information on adverse reactions was the uncontrolled study on withdrawal syndrome.

In this study, 107 hospitalised patients undergoing alcohol or opioid withdrawal received intravenous DSIP. In the original publication, DSIP was described as generally well tolerated, with headaches reported in a small number of participants [4].

A more detailed FDA analysis revealed nine cases of mild and transient adverse events. These included:

• headache,
• nausea,
• Sweating,
• dizziness.

Low blood pressure occurred in two participants at the start of the first infusion. Another participant experienced recurrent episodes of general malaise, sweating and nausea. Following the second administration, one case was described as „progressive hypotension” [1].

These results require careful interpretation.

Alcohol and opioid withdrawal on their own can cause sweating, nausea, dizziness, anxiety, insomnia and blood pressure instability. Because the study did not include a placebo group, it could not be definitively established whether DSIP was the cause of each of these symptoms.

The FDA also noted that researchers reported solubility issues with certain DSIP vials. This creates additional uncertainty as to whether the formulation may have contributed to some of the observed reactions [1].

Therefore, the available data does not allow DSIP to be described as a „side-effect-free” substance.

At the same time, symptoms reported on forums or commercial websites should not automatically be presented as scientifically proven side effects of DSIP. Human observations, theoretical risks, product quality issues and anecdotal reports represent different levels of evidence.

How robust are the human safety data for DSIP?

Safety data on DSIP in humans are poor by modern standards.

Most of the research was conducted in the 1980s and early 1990s. They usually involved a small number of participants and lasted for days rather than months or years.

Many studies were designed primarily to assess sleep or withdrawal symptoms rather than to monitor all potential adverse events in detail.

As a result, available research does not adequately determine:

• long-term toxicity,
• reproductive safety and use during pregnancy,
• safety during breastfeeding,
• immunogenicity,
• cancer risk,
• chronic organ toxicity,
• drug interactions,
• risks in people with multiple comorbid conditions,
• child safety,
• safety in elderly or frail people.

Some small studies on insomnia suggested relatively good short-term tolerance.

For example, Schneider-Helmert and Schoenenberger administered DSIP intravenously to six middle-aged individuals with chronic insomnia. They reported no daytime drowsiness or other significant side effects, although a mild stimulating effect was observed during the first hour [2].

However, six participants is definitely far too small a group to establish an overall safety profile.

Another controlled study on insomnia showed only limited clinical benefits [3]. This is also relevant when assessing safety, as tolerance alone does not imply a favourable benefit-risk balance.

The FDA found no reports of adverse reactions concerning emideltide in the FDA Adverse Event Reporting System up to 3 March 2024, nor any relevant published case reports [1].

This does not mean that DSIP is safe.

The low number of reports may be due to limited use, the sale of products outside the traditional healthcare system, inconsistent naming, failure to recognise a causal relationship, or under-reporting. The FDA also points out that traditional compounding pharmacies under Section 503A are not subject to the same adverse event reporting obligations as manufacturers of approved drugs [5].

Even less data exists for the routes of administration currently being discussed on the internet.

The FDA has found no clinical safety data for subcutaneous emideltide for the proposed use in compounded preparations [1]. Data concerning intranasal DSIP are also insufficient to establish local or systemic safety.

Historical intravenous studies cannot therefore automatically confirm the safety of intranasal DSIP aerosol or subcutaneous DSIP.

Long-term safety remains largely unknown.

Available research does not allow to determine whether repeated exposure to DSIP may cause the formation of antibodies, changes in efficacy, immunological reactions, altered response to naturally occurring peptides, endocrinological effects, organ toxicity or other delayed problems.

Can DSIP cause insomnia or worsened sleep?

DSIP may potentially be linked to worsened sleep in some situations, however insomnia has not been established as a common side effect of DSIP.

The name „delta sleep-inducing peptide” might suggest that DSIP should immediately induce sleepiness. However, human studies indicate a much more complex picture.

In a small 1981 study involving six people with chronic insomnia, mild stimulation was observed in the first hour after intravenous administration of DSIP. Sleep-promoting effects appeared mainly in the second hour [2].

Later studies were less convincing.

In a double-blind cross-over study from 1987, an improvement in certain sleep parameters was observed, but several differences compared with placebo failed to reach statistical significance. The researchers considered the overall improvement to be of little clinical significance [3].

A double-blind, 1992 study involving 16 people with chronic insomnia also yielded poor results. The researchers concluded that short-term use of DSIP is unlikely to provide significant therapeutic benefits [6].

These results show why accounts such as „DSIP didn't help me sleep” or „DSIP made my sleep worse” should not automatically be interpreted as paradoxical toxicity.

Various explanations are possible, including an underlying sleep disorder, timing of administration, natural variation between consecutive nights, other medications or substances, expectancy effects, incorrect product content, product degradation or a lack of significant effect of DSIP.

An actual adverse reaction is also possible, but current studies do not allow its frequency to be determined.

Worsening of sleep following the cessation of DSIP treatment has also been reported in some individuals undergoing opioid withdrawal. The FDA noted the re-emergence of anxiety and significant insomnia approximately 24 to 72 hours after treatment cessation in a proportion of participants who had previously achieved improvement [1].

This does not prove that DSIP caused rebound insomnia. Opioid withdrawal syndrome itself frequently causes variable severity of anxiety and sleep disturbances.

Persistent insomnia should be appropriately evaluated for recognised causes such as sleep apnoea, restless legs syndrome, circadian rhythm disorders, anxiety or mood disorders, stimulant use, alcohol, medication, pain, and other medical conditions.

Potential risks associated with nasal and injectable products

The safety of DSIP does not depend solely on the peptide itself.

Additional risk may be caused by the formulation, manufacturing quality, route of administration, sterility, storage conditions, and handling of the product.

Risks associated with DSIP for injection

Products intended for parenteral administration require rigorous quality control.

Key parameters include identity, concentration, sterility, bacterial endotoxin level, particulate matter, impurities, pH, osmolality, stability and container integrity.

Terms such as „research grade”, „high purity” or „HPLC tested” do not confirm that all these requirements have been met.

For example, the percentage purity determined using the HPLC method does not in itself confirm sterility or the absence of bacterial endotoxins.

Injection also bypasses some of the body's natural protective barriers. A contaminated product or improper administration can lead to, among other things, local inflammation, redness, swelling, cellulitis, an abscess, or a serious systemic infection.

Endotoxins can also cause inflammatory reactions even when living bacteria are no longer present.

The FDA specifically highlighted concerns regarding emideltide aggregation, peptide-related impurities, endotoxin data in injectable products, and potential immunogenicity [1,5].

Immune reactions could theoretically include both local inflammation and systemic hypersensitivity or a reduction in biological activity. However, reliable data to determine the frequency of such reactions are lacking.

Historical tolerance of intravenous DSIP also does not confirm the safety of subcutaneously administered DSIP.

Intravenous infusion and subcutaneous administration lead to different exposure profiles and involve different tissues and formulation requirements.

Risks associated with intranasal DSIP

Human studies are insufficient to establish the safety, absorption, dosing reproducibility or efficacy of DSIP nasal spray for insomnia.

Nasal preparations can potentially cause local issues such as irritation, dryness, burning, sneezing, nasal congestion, epistaxis or changes in sense of smell. These are general potential risks associated with nasal formulations and should not be presented as confirmed side effects of DSIP with a specific frequency.

Absorption can also vary significantly.

Nasal obstruction, inflammation, formulation properties, device performance, and the method of spray administration can influence the amount of material reaching the nasal mucosa and remaining on its surface.

Home-made or non-validated nasal preparations introduce additional uncertainty regarding concentration, microbial contamination, pH, preservatives and stability.

Therefore, the commercial DSIP nasal spray cannot be considered equivalent to DSIP administered intravenously in historical human studies.

Interactions of DSIP with alcohol, tirzepatide and other substances

There is no reliable clinical database regarding DSIP interactions.

Interactions with alcohol, tirzepatide, sleeping pills, antidepressants, opioids, stimulants, and other peptides have not been adequately studied.

No data on interactions does not mean that a given combination is safe.

DSIP and alcohol

Historical studies involving individuals undergoing alcohol withdrawal should not be interpreted as evidence that DSIP can be safely combined with alcohol [4].

Treatment of withdrawal syndrome takes place after stopping or significantly reducing alcohol consumption and under medical supervision.

Alcohol alone can disrupt sleep, impair coordination, affect blood pressure, cause drowsiness, and subsequently contribute to sleep fragmentation.

The effect of DSIP on sleep, arousal and blood pressure remains uncertain. Combining both substances could therefore lead to difficult-to-predict effects. However, this is a precaution resulting from the known and suspected properties of both substances, rather than a confirmed DSIP–alcohol interaction.

DSIP and tirzepatide

No clinical study has been published confirming a direct interaction between DSIP and tirzepatide.

Tirzepatide is an approved medicinal product with known gastrointestinal side effects. It may also delay gastric emptying, potentially affecting the absorption of certain oral medicines [7].

This mechanism does not automatically imply an interaction between tirzepatide and DSIP administered via injection or intranasally.

However, tirzepatide can cause nausea, vomiting, reduced food intake, and dizziness [7]. Since nausea, dizziness, and hypotension have also been reported in some participants of historical DSIP studies, the overlapping symptoms could make it difficult to determine which substance is causing them.

A person taking tirzepatide on prescription should discuss additional products with their treating physician, rather than independently adding an unapproved peptide.

DSIP and sedatives or sleeping pills

Controlled studies have not established any interaction between DSIP and:

• benzodiazepines,
• non-benzodiazepine hypnotics,
• sedative antihistamines,
• melatonin,
• with antidepressants,
• antipsychotics,
• gabapentinoids,
• other products affecting sleep.

In the case of certain combinations, there could theoretically be increased drowsiness, changes in concentration, an altered sleep pattern, or an effect on blood pressure.

However, these possibilities remain uncertain because the clinical pharmacology and interaction profile of DSIP have not been well characterised.

DSIP and opioids

Historical studies evaluated DSIP during opioid withdrawal, and mechanistic studies suggested possible links to opioid signalling [4].

The FDA indicated that stimulation of opioid pathways could theoretically be associated with reinforcing properties or abuse potential. However, the agency found no relevant studies directly assessing the abuse potential of emideltide [1].

There are therefore no reliable grounds for independently combining DSIP with opioids or medications such as methadone, buprenorphine or naltrexone.

DSIP with other peptides

Reliable interaction studies have not established the safety of combining DSIP with substances such as Semax, Selank, Epitalon, Pinealon, growth hormone secretagogues, anabolic agents or other research peptides.

The simultaneous use of multiple unapproved substances also makes the interpretation of side effects more difficult.

If headache, insomnia, dizziness, a change in blood pressure or an allergic reaction occurs, identifying the responsible substance becomes more difficult.

Does DSIP cause addiction?

DSIP has not been shown to be addictive.

There is a lack of convincing human research data indicating substance craving associated with DSIP, compulsive use, a recognised tolerance syndrome, or a clearly defined withdrawal syndrome.

However, the addictive potential has not been adequately studied.

The FDA has drawn attention to a theoretical risk arising from data suggesting that DSIP may affect the release of endorphins or signalling associated with the opioid system. Activation of opioid pathways associated with the reward system could theoretically have reinforcing properties, but the FDA has not identified relevant studies directly assessing the addictive potential of emideltide [1].

This distinction is important.

A theoretical mechanism does not constitute proof that DSIP acts as an opioid or causes opioid-like dependence.

Similarly, anxiety and insomnia reported after the completion of treatment in individuals undergoing opioid withdrawal do not prove the occurrence of DSIP withdrawal syndrome. These symptoms could have resulted from the underlying opioid withdrawal process.

Better controlled studies would be needed to distinguish between the recurrence of the original problem and the effects of DSIP withdrawal.

Who should avoid unapproved research peptides?

Since DSIP has no approved clinical indication, established formulation, or adequately characterised safety profile, it should not be used as a method of self-treatment.

Uncertainty is particularly important in the case of specific groups.

One example is pregnancy. There is a lack of adequate research regarding the reproductive and developmental safety of DSIP during pregnancy.

Safety during breastfeeding also remains unknown.

Children and young people should not receive unapproved DSIP outside of appropriately authorised trials. There is no established paediatric dose or safety standard.

Older people may be particularly vulnerable to risk in cases of frailty, a tendency to fall, cognitive impairment, low blood pressure, or the concurrent use of multiple medications.

Particular caution also applies to individuals with low blood pressure, fainting, cardiovascular diseases, or those taking blood pressure-lowering medications, as hypotension was observed in historical intravenous DSIP studies [1].

Additional uncertainty surrounds individuals with severe allergies, autoimmune diseases, previous reactions to injected peptides, immunosuppression, clotting disorders or wound healing issues.

People with sleep apnoea, severe depression, bipolar disorder, psychosis, epilepsy, substance use disorders, significant kidney or liver disease, or unexplained neurological symptoms require proper medical diagnosis rather than experimental self-treatment.

It has not been established that DSIP is a safe replacement for treatments for insomnia, narcolepsy, withdrawal syndromes or other conditions of proven efficacy.

Is DSIP approved by the FDA?

No, DSIP, free-base emideltide and emideltide acetate are not ingredients of any FDA-approved medicinal product [1].

Having an FDA substance identifier or presence in a chemical database does not mean FDA approval has been obtained.

In 2026, the FDA evaluated active substances related to emideltide for their potential inclusion on the Section 503A substance list.

It was not an application for marketing authorisation.

The FDA stated that the substances have not been sufficiently characterised, and that the evidence regarding human safety and efficacy is insufficient. The agency also pointed out concerns regarding aggregation, impurities and potential immunogenicity.

The FDA has proposed that emideltide free base and emideltide acetate should not be added to the Section 503A list [1,5].

It is also important to distinguish between compounded drugs and FDA-approved drugs.

Compounded medicines do not undergo the same pre-market assessment by the FDA in terms of safety, efficacy and manufacturing quality as authorised medicinal products [5].

Therefore, a product does not become an FDA-approved medicine simply because it has been prescribed by a clinic, prepared by a compounding pharmacy, or advertised as „pharmaceutical grade”.

The FDA also stated that it did not have sufficient information to determine whether emideltide in compounded preparations could cause harm to humans via the proposed route of administration. The agency paid particular attention to potential immunogenicity and issues concerning the characterisation of the peptide [8].

This is more precise than stating that the FDA „banned DSIP”. FDA approval status, compounding substance list decisions, import regulations, and enforcement actions are distinct regulatory issues.

Legal and regulatory status of DSIP

DSIP cannot simply be defined as „legal” or „illegal” in all countries.

Regulatory status depends on the country, the way the product is presented, the intended use, claimed medical properties, route of administration, supply chain, prescription requirements, and whether the product is indeed supplied exclusively for laboratory research.

In the European Union, a product presented as intended for treating or preventing diseases, or for modifying physiological functions through pharmacological, immunological or metabolic action, may meet the legal definition of a medicinal product [9].

Medicinal products generally require the appropriate authorisation before they can be placed on the market.

An international FDA review indicated that emideltide as the free base and acetate were not registered medicinal products in the countries analysed and did not appear in the European, Japanese or International Pharmacopoeia [5]. No DSIP medicinal product authorised by the EMA was identified.

A similar fundamental distinction applies in the UK. The MHRA regulates medicinal products, and unauthorised medicines sold online can carry both legal and health risks [10]. No MHRA-authorised DSIP product has been identified.

The mere fact that a website offers DSIP shipping to the UK does not mean that the product is an approved medicine.

Searches such as „DSIP zonder recept”, meaning „DSIP without a prescription”, can also be misleading.

The availability of a product without a prescription does not mean it is an approved OTC medicine. Approved medicines available without a prescription have undergone appropriate regulatory assessment and classification. An unapproved research peptide has not undergone such a process.

The label „research use only” does not necessarily determine the status of the product either. Genuine research reagents may be legally supplied for legitimate laboratory purposes. However, the label alone may not determine the regulatory classification if the seller simultaneously promotes the product for use in relation to sleep, insomnia, injections or other applications in humans.

Risks related to the storage, degradation and quality of the product

DSIP safety cannot be separated from product quality.

A contaminated, degraded, incorrectly concentrated or mislabelled product may pose risks other than the pharmacological action of a correctly identified DSIP.

Peptides can undergo physical and chemical changes under the influence of factors such as:

• temperature,
• moisture,
• pH,
• oxygen,
• light,
• mixing and shaking,
• concentration,
• buffer composition,
• contact surfaces.

Possible degradation processes include oxidation, hydrolysis, isomerisation, adsorption, precipitation and aggregation [11].

The rate of these processes depends on the specific peptide and formulation. General knowledge about peptides therefore does not allow a universal shelf-life for DSIP to be established.

Aggregation and impurities are particularly important from the point of view of immunological risk.

The FDA noted that emideltide for injection may be associated with an immunogenicity risk due to aggregation and peptide-related impurities. There were insufficient data to rule out such a risk [1,8].

The mere appearance of the product does not allow its quality to be determined. A clear solution may still contain chemical degradation products, microorganisms or endotoxins.

Similarly, the addition of bacteriostatic or sterile water does not sterilise non-sterile peptide powder or remove endotoxins.

Damaged packaging, missing batch number information, presence of particles, turbidity, discoloration or unverifyable test results may indicate product quality issues.

However, the absence of such signals does not constitute proof of safety.

Identity, concentration, purity, sterility, endotoxin level and stability are distinct quality parameters requiring appropriate testing.

How to interpret safety information about DSIP on Reddit and forums?

Reddit, internet forums and other communities can show what users are experiencing or discussing. However, they do not establish how often a given DSIP side effect occurs or whether it was actually caused by DSIP.

For example, a person reporting a headache after using DSIP may have actually experienced a reaction.

However, a headache can also result from sleep deprivation, dehydration, another medication, alcohol, anxiety, product contamination, incorrect concentration, a placebo or nocebo effect, or an unrelated illness.

Products discussed on the internet may also differ significantly in chemical form, purity, concentration, storage conditions and route of administration.

Some users may refer to various materials as „DSIP”. Others may fail to mention concurrently used substances or make calculation errors.

Online communities are also susceptible to selection bias. Individuals experiencing exceptionally strong positive or negative effects may be more likely to publish their experiences than those who noticed no effect.

When assessing such a report, it is worth paying attention to whether the product has been independently tested, what route of administration was used, whether other medications or alcohol were used at the same time, whether the person had pre-existing health conditions or sleep problems, and whether the symptoms subsided after stopping the product.

Even a very detailed account remains an anecdote, however, rather than a controlled clinical trial.

Serious symptoms should not be addressed using forum advice. Breathing difficulties, swelling of the face or throat, fainting, severe or persistent hypotension, chest pain, confusion, seizures, high fever, spreading redness around the injection site, or a rapidly deteriorating condition require urgent medical evaluation.

What do current evidence show, and what do they not confirm?

DSIP safety data limitations

The biggest limitation of DSIP safety research is the quality and age of the available data.

Most studies involving humans were conducted several decades ago and included small groups of participants. Adverse event reporting was usually less detailed than would be expected in a modern clinical development programme.

Some important safety data also come from open-label studies on withdrawal syndrome. Symptoms of alcohol or opioid withdrawal overlap significantly with potential adverse reactions of DSIP, making it difficult to determine causality.

Another significant limitation is the routes of administration.

Historical human studies primarily utilised intravenous administration of DSIP under supervision. Contemporary internet discussions more frequently concern subcutaneous injections or nasal preparations. These routes cannot automatically be considered equivalent.

There is a lack of adequate long-term randomised safety studies, contemporary dose-finding studies, comprehensive pharmacokinetic studies, reproductive studies, paediatric studies, formal interaction studies, and a reliable post-market surveillance system.

Additional uncertainty is caused by product variability, as modern preparations described as „research grade” or compounded may not be chemically or microbiologically equivalent to the materials used in historical research.

Regulatory applications may also change. The status described here reflects official information available up to August 2026, including the 2026 FDA assessment. If the current regulatory status is important, current information from the FDA, EMA, MHRA and relevant national regulatory authorities should be checked.

Frequently asked questions about DSIP safety

Which side effects of DSIP are best documented?

In historical intravenous studies, transient headaches, nausea, dizziness, sweating, and a few cases of low blood pressure were reported. This mainly affected individuals undergoing alcohol or opiate withdrawal [1,4].

Because withdrawal symptoms and formulation issues may also have contributed to these symptoms, the exact causal relationship with DSIP remains uncertain.

Is the DSIP peptide safe?

Currently, DSIP cannot be described as a substance with confirmed safety.

Small, short-term studies have sometimes indicated good tolerability, but they were not large or long enough to detect rare reactions, long-term toxicity, effects on reproduction, immune reactions, or important drug interactions.

The FDA stated that it does not possess sufficient information to determine whether emideltide in compounded preparations may cause harm via the proposed route of administration [8].

Can DSIP cause insomnia?

Insomnia has not been established as a common side effect of DSIP. However, short-term initial agitation and inconsistent effects on sleep have been reported [1,2].

Worsening of sleep after the administration of DSIP can have many potential causes, therefore persistent insomnia requires a proper clinical evaluation.

Can DSIP cause headache or fatigue?

Headache was reported in historical studies involving individuals undergoing withdrawal syndrome [1,4].

Fatigue has not been established as a recurring, specific adverse reaction of DSIP. The cause may also be insufficient sleep, another medicinal product, an underlying disease or other factors.

Can DSIP cause an allergic reaction?

There is a lack of reliable data regarding the frequency of such reactions.

The FDA has pointed out potential immunogenicity issues with peptide products, particularly injectable preparations, in which aggregates or impurities may be present [1,8].

Difficulty in breathing, swelling of the face or throat, widespread hives or fainting require urgent medical help.

Does DSIP interact with alcohol?

There are no controlled studies confirming that DSIP and alcohol can be used safely at the same time.

Research on alcohol withdrawal does not prove the safety of simultaneous exposure to alcohol and DSIP. Because alcohol affects sleep, coordination and blood pressure, combining it with a poorly characterised peptide introduces additional uncertainty.

Does DSIP interact with tirzepatide?

No direct study of the interaction between DSIP and tirzepatide has been conducted to confirm safety or a specific interaction.

Tirzepatide has a known effect on the digestive system and metabolism, whereas the pharmacology and interaction profile of DSIP remain poorly characterised [7]. Individuals taking tirzepatide should discuss additional substances with their attending physician.

Does DSIP cause addiction or withdrawal symptoms?

Neither an addiction syndrome nor a withdrawal syndrome associated with DSIP has been established.

However, the FDA stated that the addictive potential had not been adequately studied and pointed to theoretical concerns regarding opioid signalling [1].

Is DSIP approved by the FDA for the treatment of insomnia?

No.

DSIP, or emideltide, is not approved by the FDA for the treatment of insomnia, narcolepsy, withdrawal syndromes, or other medical indications.

The FDA's consideration of emideltide in the context of the Section 503A bulks list was a separate regulatory process and did not constitute a drug approval application [1,5].

Is DSIP approved by the EMA or MHRA?

In the analysed data, no medicinal product containing DSIP approved by the EMA or MHRA was identified.

Regulatory status is subject to change. If up-to-date marketing authorisation information is required, please consult official medicinal product databases.

Can DSIP be obtained over the counter?

Online availability does not mean that DSIP is an approved over-the-counter medicine.

In Europe and the UK, the way a substance is presented, advertised and supplied can influence whether it is subject to medicinal products legislation [9,10]. The designation „research use only” does not automatically make the use of a product by consumers for medical purposes lawful.

Is a certificate of analysis sufficient to confirm the safety of DSIP?

No.

An authentic batch-specific certificate can provide useful information about identity or chemical purity. However, it does not automatically confirm the correct vial content, sterility, endotoxin level, stability, clinical safety or suitability for injection.

Who should avoid DSIP?

Since DSIP is not approved and has been insufficiently researched, it should not be used for self-treatment.

Uncertainty is particularly important during pregnancy and breastfeeding, in children and adolescents, and in people with low blood pressure, cardiovascular disease, severe allergies, immune disorders, substance use disorders, complex pharmacotherapy regimens, or significant neurological conditions and sleep disorders.

Disclaimer

The content is strictly for educational and scientific-information purposes. It does not constitute medical advice, a diagnosis, treatment or dosage recommendations, or a recommendation for the use of DSIP.

Delta sleep-inducing peptide (DSIP/emideltide) is not approved by the US FDA, the European Medicines Agency (EMA) or the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of insomnia, withdrawal syndromes or other uses discussed in this article. Available data are limited and include small historical human studies, animal studies and mechanistic research.

The article does not recommend buying, preparing, dosing, injecting or otherwise using DSIP. To determine current legal and regulatory requirements, you should use information from the appropriate regulatory authority or consult a suitably qualified legal professional.

References

[1] U.S. Food and Drug Administration. (2026). Evaluation of emideltide-related bulk drug substances: Emideltide (free base) and emideltide acetate for inclusion on the 503A Bulk Drug Substances List. Pharmacy Compounding Advisory Committee briefing document. https://www.fda.gov/media/193344/download

[2] Schneider-Helmert, D., & Schoenenberger, G. A. (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 37(9), 913–917. https://doi.org/10.1007/BF01971753

[3] Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/

[4] Dick, P., Costa, C., Fayolle, K., Grandjean, M. E., Khoshbeen, A., & Tissot, R. (1984). DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology, 23(5), 364–371. https://doi.org/10.1159/000115715

[5] U.S. Food and Drug Administration. (2026). Pharmacy Compounding Advisory Committee meeting: Emideltide-related bulk drug substances. https://www.fda.gov/media/193774/download

[6] Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://pubmed.ncbi.nlm.nih.gov/1299794/

[7] U.S. Food and Drug Administration. (2026). Mounjaro (tirzepatide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf

[8] U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

[9] European Commission. (2025). Auxiliary medicinal products in clinical trials. https://health.ec.europa.eu/document/download/1bf35e45-134c-4f2e-9c68-0e8537eef867_en

[10] Medicines and Healthcare products Regulatory Agency. (2026). Report a suspicious online seller of medicines or medical devices. https://report-or-check-suspicious-activity.mhra.gov.uk/report

[11] Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). Stability of protein pharmaceuticals: An update. Pharmaceutical Research, 27(4), 544–575. https://doi.org/10.1007/s11095-009-0045-6